You have 10 free articles left this month. Get your freeBasic subscription now and gain instant access to more.

UPDATE 1 - Slovenian drug maker Krka's 2018 net profit rises 14%

UPDATE 1 - Slovenian drug maker Krka's 2018 net profit rises 14% Source: Krka

LJUBLJANA (Slovenia), March 21 (SeeNews) - Slovenian pharmaceuticals producer Krka [LJE:KRKG] recorded a consolidated net profit of 174 million euro ($197.8 million) in 2018, up 14% on the year, the company said on Thursday, citing unaudited data.

Consolidated revenue increased to 1.33 billion euro from 1.27 billion euro in 2017, Krka said in a bourse filing.

Krka's region of East Europe reached the highest sales figure in the group, of 412.9 million euro or 31% of total sales. Sales in East Europe rose 7% on the year in 2018.

Next came Central Europe, where sales revenue increased 5% to 318.3 million euro, or 24% of total sales.

Region West Europe followed with sales of 287.1 million euro, up 1% over 2017 and 22% of total.

Sales in Southeast Europe grew 9% to 176.2 million euro, whereas sales in the Overseas Markets region increased 12% to 43.4 million euro.

Sales in Slovenia increased to 88.9 million euro, up 3% on the year. They contributed 7% of total Krka Group sales.

Krka's consolidated EBITDA amounted to 343.3 million euro at the end of December, up 12% year-on-year, while its EBIT increased 17% to 232.7 million euro.

The Krka Group allocated 96.3 million euro to investments last year, of which 78.0 million euro to the controlling company.

The group employed 11,390 people at the end of 2018, up 5% year-on-year.

($ = 0.87953 euro)